Rheumatology & Rehabilitation Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
Clin Rheumatol. 2021 Nov;40(11):4553-4558. doi: 10.1007/s10067-021-05803-7. Epub 2021 Jun 17.
SLE disease activity score (SLE-DAS) is a novel, rapid, continuous and comprehensive score that overcomes the drawbacks of SLEDAI-2 K. Low lupus disease activity state (LLDAS) has been targeted as an endpoint in many clinical trials and as a favourable outcome in clinical practice. Therefore, our objective in the current study is to evaluate the validity of SLE-DAS for defining LLDAS as an objective in the treat-to-target strategy.
A cross-sectional study was carried out on 117 SLE patients who were diagnosed according to Systemic Lupus International Collaborating Clinics (SLICC) classification criteria for SLE. Patients were evaluated for disease activity by both SLEDAI-2 K and SLE-DAS. Additionally, patients were divided according to the SLEDAI-2 K-derived LLDAS definition into two groups: low disease activity (LDA) group and high disease activity (HDA) group. The validity of SLE-DAS for the definition of LLDAS was evaluated in comparison to SLEDAI-2 K.
SLE-DAS shows highly significant positive correlation (r = 0.743, p < 0.001) with SLEDAI-2 K. The ROC curve revealed that SLE-DAS is valid for the assessment of activity with the best detection of LLDAS was at 6.62 with 95.5% sensitivity, 79.3% specificity and 89.6% accuracy. Moreover, it had a good agreement with the SLEDAI-2 K-derived definition of LLDAS (k = 0.765, p < 0.001).
SLE-DAS is a valid score for the definition of LLDAS which can be used in the clinical practice as a simple and precise standalone criterion. Key Points • Correlation between SLEDAI-2K and SLE-DAS revealed a high significance. • Identify SLE-DAS cut-off 6.62 for the definition of LLDAS. • There is a good agreement between SLEDAI-2K-derived definition of LLDAS and SLE-DAS definition.
SLE 疾病活动评分(SLE-DAS)是一种新型的、快速的、连续的和全面的评分系统,克服了 SLEDAI-2K 的缺点。低狼疮疾病活动状态(LLDAS)已被作为许多临床试验的终点,并被作为临床实践中的有利结局。因此,我们在目前的研究中的目标是评估 SLE-DAS 用于定义 LLDAS 作为靶向治疗策略中的目标的有效性。
对 117 名根据系统性红斑狼疮国际合作诊所(SLICC)SLE 分类标准诊断的 SLE 患者进行了横断面研究。通过 SLEDAI-2K 和 SLE-DAS 评估患者的疾病活动度。此外,根据 SLEDAI-2K 衍生的 LLDAS 定义,将患者分为两组:低疾病活动度(LDA)组和高疾病活动度(HDA)组。SLE-DAS 用于定义 LLDAS 的有效性与 SLEDAI-2K 进行了比较评估。
SLE-DAS 与 SLEDAI-2K 呈显著正相关(r=0.743,p<0.001)。ROC 曲线显示,SLE-DAS 可用于评估疾病活动度,最佳检测 LLDAS 的切点为 6.62,其敏感性为 95.5%,特异性为 79.3%,准确性为 89.6%。此外,它与 SLEDAI-2K 衍生的 LLDAS 定义具有良好的一致性(k=0.765,p<0.001)。
SLE-DAS 是定义 LLDAS 的有效评分,可在临床实践中作为一种简单而精确的独立标准使用。关键点 • SLEDAI-2K 与 SLE-DAS 之间的相关性具有高度显著性。 • 确定用于定义 LLDAS 的 SLE-DAS 切点为 6.62。 • SLEDAI-2K 衍生的 LLDAS 定义与 SLE-DAS 定义之间存在良好的一致性。